

Josep Redon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1810079/publications.pdf>

Version: 2024-02-01

368
papers

70,696
citations

10351

72
h-index

631

257
g-index

410
all docs

410
docs citations

410
times ranked

64242
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	1.0	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	1.0	5,681
3	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	1.0	5,370
4	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. <i>Lancet, The</i> , 2017, 390, 2627-2642.	6.3	5,010
5	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.3	4,778
6	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.3	4,251
7	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. <i>Lancet, The</i> , 2016, 387, 1377-1396.	6.3	3,941
8	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. <i>Lancet, The</i> , 2016, 387, 1513-1530.	6.3	2,842
9	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.3	2,129
10	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. <i>Lancet, The</i> , 2017, 389, 37-55.	6.3	1,667
11	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
12	European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. <i>Journal of Hypertension</i> , 2003, 21, 821-848.	0.3	1,390
13	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.3	1,236
14	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2013, 31, 1731-1768.	0.3	1,124
15	2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. <i>Journal of Hypertension</i> , 2016, 34, 1887-1920.	0.3	898
16	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013, 31, 1925-1938.	0.3	789
17	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2014, 32, 1359-1366.	0.3	758
18	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2008, 26, 1505-1526.	0.3	707

#	ARTICLE	IF	CITATIONS
19	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018, 36, 2284-2309.	0.3	689
20	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
21	Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2002, 347, 797-805.	13.9	667
22	Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. <i>Journal of Hypertension</i> , 2005, 23, 697-701.	0.3	628
23	Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1719-1742.	0.3	620
24	Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 634-647.	5.5	591
25	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014, 23, 3-16.	0.7	565
26	European Society of Hypertension Practice Guidelines for home blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2010, 24, 779-785.	1.0	427
27	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.4	415
28	Prognostic Value of Ambulatory Blood Pressure Monitoring in Refractory Hypertension. <i>Hypertension</i> , 1998, 31, 712-718.	1.3	395
29	Antioxidant Activities and Oxidative Stress Byproducts in Human Hypertension. <i>Hypertension</i> , 2003, 41, 1096-1101.	1.3	356
30	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
31	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	0.7	351
32	Prevalence, Persistence, and Clinical Significance of Masked Hypertension in Youth. <i>Hypertension</i> , 2005, 45, 493-498.	1.3	347
33	Prevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients. <i>Hypertension</i> , 2009, 53, 466-472.	1.3	312
34	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , 2009, 27, 1360-1369.	0.3	311
35	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet</i> , 2017, 389, 2226-2237.	6.3	263
36	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 314-340.	0.7	254

#	ARTICLE	IF	CITATIONS
37	ESH Position Paper. Journal of Hypertension, 2012, 30, 837-841.	0.3	227
38	Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252.	0.3	177
39	Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. European Heart Journal, 2011, 32, 1424-1431.	1.0	175
40	Task Force II: Blood pressure measurement and cardiovascular outcome. Blood Pressure Monitoring, 2001, 6, 355-370.	0.4	170
41	Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence. Clinical Epigenetics, 2015, 7, 55.	1.8	166
42	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. Journal of the American College of Cardiology, 2012, 59, 74-83.	1.2	164
43	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	1.6	156
44	Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 2020, 80, 1-11.	1.0	156
45	An Expert Opinion From the European Society of Hypertensionâ€“European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. Hypertension, 2016, 67, 820-825.	1.3	152
46	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2020, 27, 181-205.	0.8	148
47	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331â€“288 participants. Lancet Diabetes and Endocrinology, 2015, 3, 624-637.	5.5	139
48	Blood Pressure and Obesity Exert Independent Influences on Pulse Wave Velocity in Youth. Hypertension, 2012, 60, 550-555.	1.3	136
49	Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0138618.	1.1	131
50	Microvascular brain damage with aging and hypertension. Journal of Hypertension, 2011, 29, 1469-1477.	0.3	127
51	Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement. Journal of Hypertension, 2016, 34, 1665-1677.	0.3	118
52	Ambulatory blood pressure and microalbuminuria in essential hypertension. Journal of Hypertension, 1994, 12, 947-994.	0.3	113
53	The metabolic syndrome in hypertension: European society of hypertension position statement. Journal of Hypertension, 2008, 26, 1891-1900.	0.3	107
54	Environmental Metals and Cardiovascular Disease in Adults: A Systematic Review Beyond Lead and Cadmium. Current Environmental Health Reports, 2016, 3, 416-433.	3.2	105

#	ARTICLE	IF	CITATIONS
55	Ambulatory blood pressure monitoring in normotensive children. <i>Journal of Hypertension</i> , 1994, 12, 1417-1424.	0.3	96
56	Birth Weight Influences Blood Pressure Values and Variability in Children and Adolescents. <i>Hypertension</i> , 2001, 38, 389-393.	1.3	94
57	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140) Tj ETQq1 1 0.784314 rgBT /Overl trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	1.0	92
58	Added Impact of Obesity and Insulin Resistance in Nocturnal Blood Pressure Elevation in Children and Adolescents. <i>Hypertension</i> , 2008, 51, 635-641.	1.3	91
59	Birth Weight Impacts on Wave Reflections in Children and Adolescents. <i>Hypertension</i> , 2003, 41, 646-650.	1.3	90
60	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.3	86
61	Microalbuminuria in essential hypertension: redefining the threshold. <i>Journal of Hypertension</i> , 2002, 20, 353-355.	0.3	84
62	Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2007, 25, 1327-1336.	0.3	84
63	Factors Related to the Presence of Microalbuminuria in Essential Hypertension. <i>American Journal of Hypertension</i> , 1994, 7, 801-807.	1.0	82
64	Factors associated with therapeutic inertia in hypertension: validation of a predictive model. <i>Journal of Hypertension</i> , 2010, 28, 1770-1777.	0.3	81
65	Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk. <i>Hypertension</i> , 2015, 65, 651-661.	1.3	80
66	The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth. <i>Journal of Hypertension</i> , 2006, 24, 1557-1564.	0.3	78
67	DNA methylation patterns in newborns exposed to tobacco in utero. <i>Journal of Translational Medicine</i> , 2015, 13, 25.	1.8	75
68	Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study. <i>PLoS ONE</i> , 2017, 12, e0186196.	1.1	72
69	Declining exposures to lead and cadmium contribute to explaining the reduction of cardiovascular mortality in the US population, 1988-2004. <i>International Journal of Epidemiology</i> , 2017, 46, 1903-1912.	0.9	69
70	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.3	68
71	Urinary metals and metal mixtures and oxidative stress biomarkers in an adult population from Spain: The Horteiga Study. <i>Environment International</i> , 2019, 123, 171-180.	4.8	68
72	First-year blood pressure increase steepest in low birthweight newborns. <i>Journal of Hypertension</i> , 2007, 25, 81-86.	0.3	67

#	ARTICLE	IF	CITATIONS
73	Influence of Concurrent Obesity and Low Birth Weight on Blood Pressure Phenotype in Youth. <i>Hypertension</i> , 2009, 53, 912-917.	1.3	67
74	Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. <i>American Journal of Hypertension</i> , 2004, 17, 809-816.	1.0	66
75	Associations of Birth Weight and Postnatal Weight Gain With Cardiometabolic Risk Parameters at 5 Years of Age. <i>Hypertension</i> , 2014, 63, 1326-1332.	1.3	66
76	Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report. <i>American Journal of Hypertension</i> , 2002, 15, 465-467.	1.0	65
77	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.3	65
78	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. <i>International Journal of Epidemiology</i> , 2018, 47, 872-883i.	0.9	65
79	Mechanisms of hypertension in the cardiometabolic syndrome. <i>Journal of Hypertension</i> , 2009, 27, 441-451.	0.3	63
80	Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. <i>Journal of Human Hypertension</i> , 2007, 21, 68-75.	1.0	62
81	Differences in Blood Pressure Control and Stroke Mortality Across Spain. <i>Hypertension</i> , 2007, 49, 799-805.	1.3	61
82	Obesity, Body Fat Distribution, and Ambulatory Blood Pressure in Children and Adolescents. <i>Journal of Clinical Hypertension</i> , 2001, 3, 362-367.	1.0	60
83	Updated ESH position paper on interventional therapy of resistant hypertension. <i>EuroIntervention</i> , 2013, 9, R58-R66.	1.4	60
84	Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension. <i>Hypertension</i> , 2005, 45, 1125-1130.	1.3	59
85	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 945-960.	0.5	59
86	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. <i>Journal of Hypertension</i> , 2013, 31, 2018-2024.	0.3	58
87	Urinary exosome miR-146a is a potential marker of albuminuria in essential hypertension. <i>Journal of Translational Medicine</i> , 2018, 16, 228.	1.8	58
88	Anthropometric Indicators as a Tool for Diagnosis of Obesity and Other Health Risk Factors: A Literature Review. <i>Frontiers in Psychology</i> , 2021, 12, 631179.	1.1	58
89	Clinical inertia in diagnosis and treatment of hypertension in primary care: Quantification and associated factors. <i>Blood Pressure</i> , 2010, 19, 3-10.	0.7	56
90	Impact of hypertension on mortality and cardiovascular disease burden in patients with cardiovascular risk factors from a general practice setting. <i>Journal of Hypertension</i> , 2016, 34, 1075-1083.	0.3	55

#	ARTICLE	IF	CITATIONS
91	Nocturnal Blood Pressure Versus Nondipping Pattern. <i>Hypertension</i> , 2008, 51, 41-42.	1.3	54
92	Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). <i>Hypertension</i> , 2012, 60, 1400-1406.	1.3	54
93	Central blood pressure and pulse wave amplification across the spectrum of peripheral blood pressure in overweight and obese youth. <i>Journal of Hypertension</i> , 2016, 34, 1389-1395.	0.3	53
94	The spectrum of circadian blood pressure changes in type I diabetic patients. <i>Journal of Hypertension</i> , 2001, 19, 1421-1428.	0.3	52
95	Nocturnal blood pressure and progression to end-stage renal disease or death in nondiabetic chronic kidney disease stages 3 and 4. <i>Journal of Hypertension</i> , 2010, 28, 602-607.	0.3	52
96	Prognostic Value of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension. <i>Hypertension</i> , 2014, 64, 1228-1234.	1.3	52
97	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016, 34, 1480-1488.	0.3	52
98	Arsenic exposure, diabetes-related genes and diabetes prevalence in a general population from Spain. <i>Environmental Pollution</i> , 2018, 235, 948-955.	3.7	52
99	LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortegea-Liposcale Follow-up Study. <i>International Journal of Cardiology</i> , 2018, 264, 172-178.	0.8	52
100	Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. <i>Journal of Hypertension</i> , 2006, 24, 663-669.	0.3	50
101	Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. <i>Blood Pressure Monitoring</i> , 2002, 7, 111-116.	0.4	49
102	Plasma selenium levels and oxidative stress biomarkers: A gene-environment interaction population-based study. <i>Free Radical Biology and Medicine</i> , 2014, 74, 229-236.	1.3	49
103	Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2017, 18, 717.	1.8	49
104	Sexual Dimorphism in the Transition From Masked to Sustained Hypertension in Healthy Youths. <i>Hypertension</i> , 2013, 62, 410-414.	1.3	48
105	The polypill in cardiovascular prevention. <i>Journal of Hypertension</i> , 2017, 35, 1546-1553.	0.3	48
106	Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritis. <i>Journal of Nephrology</i> , 2021, 34, 1157-1167.	0.9	48
107	Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia. <i>Journal of Medical Virology</i> , 2020, 92, 1799-1801.	2.5	48
108	Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. <i>Journal of Human Hypertension</i> , 2001, 15, 849-856.	1.0	47

#	ARTICLE	IF	CITATIONS
109	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47
110	Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension. <i>Hypertension</i> , 2002, 39, 794-798.	1.3	46
111	Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. <i>Clinical Rheumatology</i> , 2007, 26, 971-972.	1.0	46
112	Prevalencia de fibrilaci3n auricular y uso de f3rmacos antitromb3ticos en el paciente hipertenso 65 a±os. El registro FAPRES. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 943-950.	0.6	46
113	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. <i>EuroIntervention</i> , 2014, 9, 1027-1035.	1.4	46
114	Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries. <i>Journal of Hypertension</i> , 2019, 37, 380-388.	0.3	45
115	Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 85-89.	0.4	44
116	Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. <i>Pharmacogenomics Journal</i> , 2005, 5, 14-20.	0.9	44
117	Urinary 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxo-dG), a reliable oxidative stress marker in hypertension. <i>Free Radical Research</i> , 2007, 41, 546-554.	1.5	44
118	Isolated Systolic Hypertension in Young People Is Not Spurious and Should Be Treated. <i>Hypertension</i> , 2016, 68, 276-280.	1.3	44
119	Urine cadmium levels and albuminuria in a general population from Spain: A gene-environment interaction analysis. <i>Environment International</i> , 2017, 106, 27-36.	4.8	44
120	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1441-1455.	0.3	44
121	Inadequate Cytoplasmic Antioxidant Enzymes Response Contributes to the Oxidative Stress in Human Hypertension. <i>American Journal of Hypertension</i> , 2007, 20, 62-69.	1.0	43
122	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. <i>Journal of Hypertension</i> , 2020, 38, 799-812.	0.3	43
123	Differential prognostic effect of systolic blood pressure on mortality according to left ventricular function in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 38-44.	2.9	42
124	Microalbuminuria and oxidative stress in essential hypertension. <i>Journal of Internal Medicine</i> , 2004, 255, 588-594.	2.7	41
125	Renal protection by antihypertensive drugs. <i>Journal of Hypertension</i> , 1998, 16, 2091-2100.	0.3	40
126	Independent impact of obesity and fat distribution in hypertension prevalence and control in the elderly. <i>Journal of Hypertension</i> , 2008, 26, 1757-1764.	0.3	40

#	ARTICLE	IF	CITATIONS
127	Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. <i>Journal of Hypertension</i> , 2011, 29, 492-500.	0.3	40
128	A gene-environment interaction analysis of plasma selenium with prevalent and incident diabetes: The Hortega study. <i>Redox Biology</i> , 2017, 12, 798-805.	3.9	40
129	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
130	Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. <i>Journal of Hypertension</i> , 2017, 35, 1727-1741.	0.3	39
131	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	1.2	39
132	Common Variants of the Liver Fatty Acid Binding Protein Gene Influence the Risk of Type 2 Diabetes and Insulin Resistance in Spanish Population. <i>PLoS ONE</i> , 2012, 7, e31853.	1.1	39
133	Renin polymorphisms and haplotypes are associated with blood pressure levels and hypertension risk in postmenopausal women. <i>Journal of Hypertension</i> , 2008, 26, 230-237.	0.3	38
134	Impact of ESH and AAP hypertension guidelines for children and adolescents on office and ambulatory blood pressure-based classifications. <i>Journal of Hypertension</i> , 2019, 37, 2414-2421.	0.3	38
135	European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. <i>Journal of Hypertension</i> , 2009, 27, 207-211.	0.3	37
136	Physician attitudes to blood pressure control. <i>Journal of Hypertension</i> , 2011, 29, 1633-1640.	0.3	37
137	Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. <i>Journal of Hypertension</i> , 2012, 30, 67-74.	0.3	36
138	Urinary dedifferentiated podocytes as a non-invasive biomarker of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 780-789.	0.4	36
139	Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. <i>Journal of Hypertension</i> , 2018, 36, 1840-1846.	0.3	36
140	Reproducibility of ambulatory blood pressure monitoring in children. <i>Journal of Hypertension</i> , 1993, 11, S288-S289.	0.3	35
141	Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. <i>Journal of Hypertension</i> , 1997, 15, 79-86.	0.3	35
142	Measurement of microalbuminuria – what the nephrologist should know. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 573-576.	0.4	35
143	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	1.0	35
144	Arsenic, cadmium, and selenium exposures and bone mineral density-related endpoints: The HORTEGA study. <i>Free Radical Biology and Medicine</i> , 2021, 162, 392-400.	1.3	35

#	ARTICLE	IF	CITATIONS
145	A novel CYBA variant, the 675A/T polymorphism, is associated with essential hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1620-1626.	0.3	34
146	Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERICA-HTA study. <i>Blood Pressure</i> , 2007, 16, 20-27.	0.7	34
147	Association of Arsenic Exposure With Cardiac Geometry and Left Ventricular Function in Young Adults. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009018.	1.3	34
148	Practical solutions to the challenges of uncontrolled hypertension: a white paper. <i>Journal of Hypertension</i> , 2008, 26, S1-S14.	0.3	33
149	Determinants of Cardiometabolic Risk Factors in the First Decade of Life. <i>Hypertension</i> , 2018, 71, 437-443.	1.3	33
150	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e021038.	0.8	33
151	Risk factors associated with retinal vein occlusion. <i>International Journal of Clinical Practice</i> , 2014, 68, 871-881.	0.8	32
152	Urinary- and Plasma-Derived Exosomes Reveal a Distinct MicroRNA Signature Associated With Albuminuria in Hypertension. <i>Hypertension</i> , 2021, 77, 960-971.	1.3	32
153	Blood Pressure and Estimated Risk of Stroke in the Elderly Population of Spain. <i>Stroke</i> , 2007, 38, 1167-1173.	1.0	31
154	European Society of Hypertension Working Group on Obesity: background, aims and perspectives. <i>Journal of Hypertension</i> , 2007, 25, 897-900.	0.3	31
155	The Kidney in Obesity. <i>Current Hypertension Reports</i> , 2015, 17, 555.	1.5	31
156	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017, 70, 938-948.	1.3	31
157	Control de la presión arterial de los pacientes diabéticos en el ámbito de atención primaria. Estudio DIAPA. <i>Medicina Clínica</i> , 2003, 120, 529-534.	0.3	31
158	Relationship between birth weight and awake blood pressure in children and adolescents in absence of intrauterine growth retardation. <i>American Journal of Hypertension</i> , 1996, 9, 787-794.	1.0	30
159	Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension. <i>American Journal of Hypertension</i> , 2001, 14, 364-370.	1.0	30
160	Prevalence and factors related to urinary albumin excretion in obese youths. <i>Journal of Hypertension</i> , 2013, 31, 2230-2236.	0.3	30
161	Influence of the I/D Polymorphism of the Angiotensin-Converting Enzyme Gene on the Outcome of Microalbuminuria in Essential Hypertension. <i>Hypertension</i> , 2000, 35, 490-495.	1.3	29
162	Reproducibility and validity of ambulatory blood pressure monitoring in children. <i>American Journal of Hypertension</i> , 2002, 15, S69-S73.	1.0	29

#	ARTICLE	IF	CITATIONS
163	Development of microalbuminuria in essential hypertension. <i>Current Hypertension Reports</i> , 2006, 8, 171-177.	1.5	29
164	Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. <i>Current Medical Research and Opinion</i> , 2008, 24, 659-670.	0.9	29
165	Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 734-739.	1.1	29
166	Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. <i>Blood Pressure</i> , 2016, 25, 333-336.	0.7	29
167	Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 180.	0.7	29
168	Impact of Obesity in Kidney Diseases. <i>Nutrients</i> , 2021, 13, 4482.	1.7	29
169	Association of a Mineralocorticoid Receptor Gene Polymorphism With Hypertension in a Spanish Population. <i>American Journal of Hypertension</i> , 2009, 22, 649-655.	1.0	28
170	The normal circadian pattern of blood pressure: implications for treatment. <i>International Journal of Clinical Practice</i> , 2004, 58, 3-8.	0.8	27
171	Acute kidney injury in heart failure: a population study. <i>ESC Heart Failure</i> , 2020, 7, 415-422.	1.4	27
172	Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 589-596.	0.7	26
173	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.3	26
174	Pulse pressure amplification and its determinants. <i>Blood Pressure</i> , 2016, 25, 21-27.	0.7	26
175	Ambulatory blood pressure monitoring in children and adolescents. <i>Journal of Hypertension</i> , 2000, 18, 1351-1354.	0.3	25
176	The Effect Duration of Candesartan Cilexetil Once Daily, in Comparison with Enalapril Once Daily, in Patients with Mild to Moderate Hypertension. <i>Blood Pressure</i> , 2001, 10, 43-51.	0.7	25
177	Diagnosis and Treatment of Hypertension in Children. <i>Current Hypertension Reports</i> , 2010, 12, 480-486.	1.5	25
178	Should we look for silent pulmonary embolism in patients with deep venous thrombosis?. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 178.	0.7	25
179	Influence of obesity in central blood pressure. <i>Journal of Hypertension</i> , 2015, 33, 308-313.	0.3	25
180	Assessing ambulatory blood pressure in renal diseases: facts and concerns. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2564-2568.	0.4	24

#	ARTICLE	IF	CITATIONS
181	Urinary Albumin Excretion and Glomerular Filtration Rate across the Spectrum of Glucose Abnormalities in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S236-S245.	3.0	24
182	Different Impacts of Cardiovascular Risk Factors on Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2011, 12, 6146-6163.	1.8	24
183	Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population. <i>European Journal of Clinical Investigation</i> , 2012, 42, 171-178.	1.7	24
184	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 880.e1-880.e64.	0.6	24
185	Ambulatory Blood Pressure Monitoring Is Ready to Replace Clinic Blood Pressure in the Diagnosis of Hypertension. <i>Hypertension</i> , 2014, 64, 1169-1174.	1.3	24
186	Peripheral blood mitochondrial DNA content in relation to circulating metabolites and inflammatory markers: A population study. <i>PLoS ONE</i> , 2017, 12, e0181036.	1.1	24
187	Obesity modifies the relationship between ambulatory blood pressure and natriuresis in children. <i>Blood Pressure Monitoring</i> , 2000, 5, 275-280.	0.4	23
188	Determinants of urinary albumin excretion reduction in essential hypertension: a long-term follow-up study. <i>Journal of Hypertension</i> , 2006, 24, 2277-2284.	0.3	23
189	Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: Results from the population-based Hortega study. <i>Atherosclerosis</i> , 2010, 211, 203-209.	0.4	23
190	The Importance of 24-Hour Ambulatory Blood Pressure Monitoring in Patients at Risk of Cardiovascular Events. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 13-18.	1.0	23
191	Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 22-32.	0.8	23
192	Catastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation. <i>Clinical Rheumatology</i> , 2007, 26, 991-993.	1.0	22
193	Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 293-298.	1.5	22
194	Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Intensifying Treatment. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 213-219.	1.0	22
195	Global Cardiovascular Risk Assessment: Strengths and Limitations. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 87-90.	1.0	22
196	Risperidone and severe cerivastatin-induced rhabdomyolysis. <i>Journal of Internal Medicine</i> , 2002, 251, 177-178.	2.7	21
197	Is the Physician's Behavior in Dyslipidemia Diagnosis in Accordance with Guidelines? Cross-Sectional Escarval Study. <i>PLoS ONE</i> , 2014, 9, e91567.	1.1	21
198	Chronic kidney disease as a cardiovascular risk factor. <i>Journal of Hypertension</i> , 2020, 38, 2110-2121.	0.3	21

#	ARTICLE	IF	CITATIONS
199	Body weight changes and the A-6G polymorphism of the angiotensinogen gene. <i>International Journal of Obesity</i> , 2002, 26, 1173-1178.	1.6	19
200	Urinary Albumin Excretion. <i>Hypertension</i> , 2005, 46, 19-20.	1.3	19
201	Rationale and methods of the cardiometabolic valencian study (escarval-risk) for validation of risk scales in mediterranean patients with hypertension, diabetes or dyslipidemia. <i>BMC Public Health</i> , 2010, 10, 717.	1.2	19
202	Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis. <i>Clinical Science</i> , 2018, 132, 569-579.	1.8	19
203	CX3CR1/CX3CL1 Axis Mediates Platelet Leukocyte Adhesion to Arterial Endothelium in Younger Patients with a History of Idiopathic Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 562-571.	1.8	19
204	Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2022, 19, 8.	2.0	19
205	Polymorphism insertion/deletion of the ACE gene and ambulatory blood pressure circadian variability in essential hypertension. <i>Blood Pressure Monitoring</i> , 2001, 6, 27-32.	0.4	18
206	Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 147-156.	1.0	18
207	Is There a Predictive Profile for Clinical Inertia in Hypertensive Patients?. <i>Drugs and Aging</i> , 2011, 28, 981-992.	1.3	18
208	Sympathetic neural activity, metabolic parameters and cardiorespiratory fitness in obese youths. <i>Journal of Hypertension</i> , 2017, 35, 571-577.	0.3	18
209	Therapeutic Potential of Extracellular Vesicles in Hypertension-Associated Kidney Disease. <i>Hypertension</i> , 2021, 77, 28-38.	1.3	18
210	Genomic and Metabolomic Profile Associated to Microalbuminuria. <i>PLoS ONE</i> , 2014, 9, e98227.	1.1	18
211	OASIS-HT: design of a pharmacogenomic dose-finding study. <i>Pharmacogenomics</i> , 2005, 6, 755-775.	0.6	17
212	Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. <i>International Journal of Clinical Practice</i> , 2009, 63, 71-81.	0.8	17
213	Impact of cardiovascular risk factors on oxidative stress and DNA damage in a high risk Mediterranean population. <i>Free Radical Research</i> , 2009, 43, 1179-1186.	1.5	17
214	Special Considerations for Antihypertensive Agents in Dialysis Patients. <i>Blood Purification</i> , 2010, 29, 93-98.	0.9	17
215	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017, 42, 198-225.	1.1	17
216	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. <i>Journal of Hypertension</i> , 2020, 38, 2036-2042.	0.3	17

#	ARTICLE	IF	CITATIONS
217	The impact of birth weight on pulse pressure during adolescence. <i>Blood Pressure Monitoring</i> , 2004, 9, 187-192.	0.4	16
218	Twenty-four-hour ambulatory heart rate and organ damage in primary hypertension. <i>Blood Pressure</i> , 2010, 19, 104-109.	0.7	16
219	Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: Study in two Spanish populations. <i>Atherosclerosis</i> , 2011, 219, 900-906.	0.4	16
220	Microalbuminuria as Surrogate Endpoint in Therapeutic Trials. <i>Current Hypertension Reports</i> , 2012, 14, 345-349.	1.5	16
221	Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw387.	0.4	16
222	Diastolic Left Ventricular Function in Relation to Circulating Metabolic Biomarkers in a General Population. <i>Journal of the American Heart Association</i> , 2016, 5, e002681.	1.6	16
223	Microalbuminuria as an intermediate endpoint in essential hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1679-1681.	0.3	15
224	Role of dihydropyridinic calcium channel blockers in the management of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 91-105.	0.6	15
225	Impact of abdominal obesity and ambulatory blood pressure in the diagnosis of left ventricular hypertrophy in never treated hypertensives. <i>Medicina Clínica</i> , 2014, 142, 235-242.	0.3	15
226	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 51-59.	1.0	15
227	Redefining hypertension in children and adolescents: A review of the evidence considered by the European Society of Hypertension and American Academy of Pediatrics guidelines. <i>Journal of Hypertension</i> , 2020, 38, 196-200.	0.3	15
228	Ambulatory blood pressure during diseases of the kidney. <i>Blood Pressure Monitoring</i> , 1999, 4, 267-274.	0.4	15
229	Direct and surrogate measures of the white-coat effect. <i>Journal of Hypertension</i> , 2000, 18, 379-382.	0.3	14
230	Thrombocytopenia Associated With Levodopa Treatment. <i>Archives of Internal Medicine</i> , 2003, 163, 735.	4.3	14
231	Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HEROIC Study. <i>Journal of Clinical Hypertension</i> , 2010, 12, 335-344.	1.0	14
232	Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 786-792.	0.8	14
233	Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe. <i>Journal of Hypertension</i> , 2015, 33, 2250-2256.	0.3	14
234	The nutrigenetic influence of the interaction between dietary vitamin E and TXN and COMT gene polymorphisms on waist circumference: a case control study. <i>Journal of Translational Medicine</i> , 2015, 13, 286.	1.8	14

#	ARTICLE	IF	CITATIONS
235	Multimorbidity and acute heart failure in internal medicine. <i>International Journal of Cardiology</i> , 2017, 232, 208-215.	0.8	14
236	Optimization of small RNA library preparation protocol from human urinary exosomes. <i>Journal of Translational Medicine</i> , 2020, 18, 132.	1.8	14
237	Discordant Response of Glutathione and Thioredoxin Systems in Human Hypertension?. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 507-514.	2.5	13
238	Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de España. Estudio RIMHA. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1022-1031.	0.6	13
239	Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment. <i>Journal of Hypertension</i> , 2013, 31, 1683-1691.	0.3	13
240	Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. <i>Journal of Hypertension</i> , 2014, 32, 1551-1552.	0.3	13
241	Intensive blood pressure lowering: a practical review. <i>Clinical Hypertension</i> , 2020, 26, 21.	0.7	13
242	Assessment of blood pressure early morning rise. <i>Blood Pressure Monitoring</i> , 2001, 6, 207-210.	0.4	12
243	Body weight variation and control of cardiovascular risk factors in essential hypertension. <i>Blood Pressure</i> , 2009, 18, 247-254.	0.7	12
244	Home blood pressure control is low during the critical morning hours in patients with hypertension: the SURGE observational study. <i>Family Practice</i> , 2012, 29, 421-426.	0.8	12
245	Impact of obesity-related genes in Spanish population. <i>BMC Genetics</i> , 2013, 14, 111.	2.7	12
246	Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study. <i>Blood Pressure</i> , 2014, 23, 181-188.	0.7	12
247	Expertise. <i>Journal of Hypertension</i> , 2017, 35, 1564-1566.	0.3	12
248	Cohort profile: the Horteaga Study for the evaluation of non-traditional risk factors of cardiometabolic and other chronic diseases in a general population from Spain. <i>BMJ Open</i> , 2019, 9, e024073.	0.8	12
249	Nocturnal hypertension: Will control of nighttime blood pressure prevent progression of diabetic renal disease?. <i>Current Hypertension Reports</i> , 2004, 6, 393-399.	1.5	11
250	Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression?. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 448-452.	1.0	11
251	Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. <i>Journal of Hypertension</i> , 2010, 28, 865-874.	0.3	11
252	European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. <i>Journal of Hypertension</i> , 2011, 29, 189-193.	0.3	11

#	ARTICLE	IF	CITATIONS
253	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	2.7	11
254	Do Genes Modify the Association of Selenium and Lipid Levels?. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1352-1362.	2.5	10
255	Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. <i>Journal of Hypertension</i> , 2016, 34, 359-367.	0.3	10
256	Genomic and Metabolomic Profile Associated to Clustering of Cardio-Metabolic Risk Factors. <i>PLoS ONE</i> , 2016, 11, e0160656.	1.1	10
257	Left Ventricular Hypertrophy in the Spanish Hypertensive Population. The ERIC-HTA Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 136-142.	0.4	9
258	Discrepancies in office and ambulatory blood pressure in adolescents: help or hindrance?. <i>Pediatric Nephrology</i> , 2008, 23, 341-345.	0.9	9
259	Urinary podocyte-associated molecules and albuminuria in hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1712-1718.	0.3	9
260	Decreased Urinary Levels of SIRT1 as Non-Invasive Biomarker of Early Renal Damage in Hypertension. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6390.	1.8	9
261	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2020, 38, 2050-2058.	0.3	9
262	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.3	9
263	Small Rab GTPases in Intracellular Vesicle Trafficking: The Case of Rab3A/Raphillin-3A Complex in the Kidney. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7679.	1.8	9
264	Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. <i>Journal of Clinical Virology</i> , 2021, 142, 104943.	1.6	9
265	Exosomal and Plasma Non-Coding RNA Signature Associated with Urinary Albumin Excretion in Hypertension. <i>International Journal of Molecular Sciences</i> , 2022, 23, 823.	1.8	9
266	Gene-environment interaction analysis of redox-related metals and genetic variants with plasma metabolic patterns in a general population from Spain: The Ortega Study. <i>Redox Biology</i> , 2022, 52, 102314.	3.9	9
267	Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. <i>American Journal of Hypertension</i> , 2001, 14, A248.	1.0	8
268	Polymorphisms of the Renin-Angiotensin System Influence Height in Normotensive Women in a Spanish Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2301-2305.	1.8	8
269	Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMHA study. <i>Blood Pressure</i> , 2006, 15, 237-244.	0.7	8
270	The metabolic syndrome in hypertension: Diagnostic and therapeutic implications. <i>Current Hypertension Reports</i> , 2007, 9, 305-313.	1.5	8

#	ARTICLE	IF	CITATIONS
271	Genetic bases of urinary albumin excretion and related traits in hypertension. <i>Journal of Hypertension</i> , 2010, 28, 213-225.	0.3	8
272	Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2018, 20, 356-365.	1.0	8
273	Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain. <i>International Journal of Cardiology</i> , 2019, 293, 260-265.	0.8	8
274	Analysis of LDL and HDL size and number by nuclear magnetic resonance in a healthy working population: The LipoLab Study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13610.	0.8	8
275	Treatment of Patients with Essential Hypertension and Microalbuminuria. <i>Drugs</i> , 1997, 54, 857-866.	4.9	7
276	Prevalence of Atrial Fibrillation and Use of Antithrombotics in Hypertensive Patients Aged ≥65 Years. The FAPRES Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 943-950.	0.4	7
277	Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 155-164.	0.9	7
278	Morning and smooth 24-h ambulatory blood pressure control is not achieved in general practice. <i>Journal of Hypertension</i> , 2013, 31, 616-623.	0.3	7
279	Renal function and attributable risk of death and cardiovascular hospitalization in patients with cardiovascular risk factors from a registry-based cohort. <i>Journal of Hypertension</i> , 2016, 34, 2266-2273.	0.3	7
280	Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes. <i>American Journal of Hypertension</i> , 2016, 29, 1055-1062.	1.0	7
281	Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. <i>Current Diabetes Reports</i> , 2002, 2, 539-544.	1.7	6
282	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2010, 28, 2219-2226.	0.3	6
283	Rabphilin involvement in filtration and molecular uptake in <i>Drosophila</i> nephrocytes suggests a similar role in human podocytes. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	6
284	Epidemiology and Consequences of Childhood Hypertension. , 2008, , 637-644.		6
285	Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study. <i>Journal of Human Hypertension</i> , 2004, 18, 25-31.	1.0	5
286	Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients. <i>Clinical Drug Investigation</i> , 2009, 29, 459-469.	1.1	5
287	The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2). <i>Hypertension Research</i> , 2013, 36, 322-327.	1.5	5
288	Carotid-femoral pulse wave velocity assessment by two different methods. <i>Journal of Hypertension</i> , 2015, 33, 1868-1875.	0.3	5

#	ARTICLE	IF	CITATIONS
289	The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study. <i>Primary Care Diabetes</i> , 2020, 14, 678-684.	0.9	5
290	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.3	5
291	Secondary Hypertension in Children and Adolescents. , 2004, , 279-304.		5
292	Overview of ambulatory blood pressure monitoring in childhood and pregnancy. <i>Blood Pressure Monitoring</i> , 2001, 6, 317-321.	0.4	4
293	New insights into urinary proteins as markers of cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2006, 24, 447-449.	0.3	4
294	Comment on ESH position paper. <i>Journal of Hypertension</i> , 2012, 30, 2443.	0.3	4
295	The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study. <i>Blood Pressure</i> , 2013, 22, 377-385.	0.7	4
296	Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016, 34, 2303-2304.	0.3	4
297	Expertise: No Longer a Sine Qua Non for Guideline Authors?. <i>Hypertension</i> , 2017, 70, 235-237.	1.3	4
298	Unraveling new factors associated with hypertension. <i>Journal of Hypertension</i> , 2020, 38, 30-32.	0.3	4
299	The Rab-Rabphilin system in injured human podocytes stressed by glucose overload and angiotensin II. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F178-F191.	1.3	4
300	Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage. <i>Scientific Reports</i> , 2021, 11, 15287.	1.6	4
301	The Role of Ambulatory Blood Pressure Monitoring in Diagnosis of Hypertension and Evaluation of Target Organ Damage. , 2011, , 517-528.		4
302	Wytyczne ESH/ESC dotyczÄ...ce postÄ™powania w nadciÄŃnieniu tÄ™tnicznym w 2013 roku. <i>Kardiologia Polska</i> , 2013, 71, 27-118.	0.3	4
303	New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone. <i>Cardiovascular Research</i> , 2022, 118, e36-e37.	1.8	4
304	Ambulatory blood pressure for special groups. <i>Blood Pressure Monitoring</i> , 2000, 5, 35-37.	0.4	3
305	The impact of occult renal failure on the cardiovascular risk stratification in an elderly population: The PREVÄ©CTUS study. <i>Blood Pressure</i> , 2008, 17, 212-219.	0.7	3
306	Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 452-459.	0.8	3

#	ARTICLE	IF	CITATIONS
307	Mejorando el conocimiento de la hipertensi3n arterial resistente: u es relevante?. Revista Espanola De Cardiologia, 2014, 67, 251-253.	0.6	3
308	Combining -omics in the search for mechanisms in complex trait diseases. Journal of Hypertension, 2015, 33, 698-699.	0.3	3
309	Identifying poor cardiorespiratory fitness in overweight and obese children and adolescents by using heart rate variability analysis under resting conditions. Blood Pressure, 2020, 29, 13-20.	0.7	3
310	Genetic variation and urine cadmium levels: ABCC1 effects in the Strong Heart Family Study. Environmental Pollution, 2021, 276, 116717.	3.7	3
311	Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain. International Journal of Environmental Research and Public Health, 2021, 18, 9853.	1.2	3
312	Prognostic value of diagnostic scales in community-acquired sepsis mortality at an emergency service. Prognosis in community-acquired sepsis. BMC Emergency Medicine, 2021, 21, 161.	0.7	3
313	Diagnosis of high blood pressure in children by means of ambulatory blood pressure monitoring. Current Hypertension Reports, 2001, 3, 89-90.	1.5	2
314	Managing Resistant Hypertension: Not Just a Question of Numbers. American Journal of Hypertension, 2005, 18, 1541-1542.	1.0	2
315	High-Density Lipoprotein Cholesterol and Cardiovascular Disease in Spanish Hypertensive Women. The RIMHA Study. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1022-1031.	0.4	2
316	Issues in the development of new combinations of blood pressure lowering drugs. Journal of Hypertension, 2010, 28, 2494-2496.	0.3	2
317	Agreement within Europe about antihypertensive treatment and education  results from the European Society of Hypertension questionnaire. Journal of Hypertension, 2010, 28, 1593-1594.	0.3	2
318	Improving Knowledge of Arterial Resistant Hypertension: What Is Relevant?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 251-253.	0.4	2
319	Improving Mortality Prediction in Cardiovascular Risk Patients by Balancing Classes. , 2015, , .		2
320	Unusual Case of Severe Hypertension in a 20-Year-Old Woman. Hypertension, 2015, 66, 1093-1097.	1.3	2
321	Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials. Journal of Hypertension, 2016, 34, 1489-1491.	0.3	2
322	Executive Summary of the Joint Position Paper on Renal Denervation of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the European Society of Hypertension (ESH). CardioVascular and Interventional Radiology, 2016, 39, 1681-1683.	0.9	2
323	Controversies in blood-pressure goals among the elderly. Nature Reviews Cardiology, 2017, 14, 193-194.	6.1	2
324	Impact of Acute Hemoglobin Falls in Heart Failure Patients: A Population Study. Journal of Clinical Medicine, 2020, 9, 1869.	1.0	2

#	ARTICLE	IF	CITATIONS
325	Supervised Analysis for Phenotype Identification: The Case of Heart Failure Ejection Fraction Class. <i>Bioengineering</i> , 2021, 8, 85.	1.6	2
326	Gender differences related to the presence of atrial fibrillation in older hypertensive patients. <i>World Journal of Cardiology</i> , 2013, 5, 124.	0.5	2
327	Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 255-260.	0.3	2
328	Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. , 2009, 119, 255-60.		2
329	Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. <i>Scientific Reports</i> , 2022, 12, 6123.	1.6	2
330	Insights From Matched Office and Ambulatory Blood Pressure in Youth: Clinical Relevance. <i>Hypertension</i> , 2022, 79, 1237-1246.	1.3	2
331	Oxidative stress and early organ damage in essential hypertension. <i>American Journal of Hypertension</i> , 2001, 14, A248-A249.	1.0	1
332	Predictors of Progression in Hypertensive Renal Disease in Children. <i>Journal of Clinical Hypertension</i> , 2004, 6, 186-191.	1.0	1
333	Blood pressure control and stroke mortality across populations. <i>Current Hypertension Reports</i> , 2007, 9, 440-441.	1.5	1
334	Response to Timing of Antihypertensive Therapy and Circadian Blood Pressure Pattern. <i>Hypertension</i> , 2009, 53, .	1.3	1
335	Response to Nondipping in Patients With Hypertension. <i>Hypertension</i> , 2009, 53, .	1.3	1
336	The risk of visit-to-visit blood pressure variability in chronic kidney disease. <i>Journal of Hypertension</i> , 2016, 34, 188-190.	0.3	1
337	Reply. <i>Journal of Hypertension</i> , 2016, 34, 2102.	0.3	1
338	Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 633-641.	0.4	1
339	Renal function and attributable risk of death and cardiovascular hospitalization in participants with diabetes from a registry-based cohort. <i>Primary Care Diabetes</i> , 2021, 15, 88-94.	0.9	1
340	Cardiovascular system in the sars-CoV-2: impact of therapies. <i>Journal of Hypertension</i> , 2021, 39, 1306-1308.	0.3	1
341	Ambulatory Blood Pressure Methodology and Norms in Children. , 2004, , 107-120.		1
342	Body weight variation and control of cardiovascular risk factors in essential hypertension. <i>Blood Pressure</i> , 2009, 18, 247-254.	0.7	1

#	ARTICLE	IF	CITATIONS
343	24-hour Ambulatory BP Monitoring and Home BP Measurements in Resistant Hypertension. , 2013, , 95-105.		1
344	Complexity Levels in Patients With Heart Failure Diagnostic Codes in a Population. Revista Espanola De Cardiologia (English Ed), 2018, 71, 687-688.	0.4	1
345	Biofluid Specificity of Long Non-Coding RNA Profile in Hypertension: Relevance of Exosomal Fraction. International Journal of Molecular Sciences, 2022, 23, 5199.	1.8	1
346	Comparison among indirect methods used for assesing arterial stiffness in clinical settings. American Journal of Hypertension, 1999, 12, 176.	1.0	0
347	Memorial to Manuel Luque Otero, MD. Hypertension, 2007, 50, 595-595.	1.3	0
348	Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial. International Journal of Cardiology, 2009, 137, S39-S40.	0.8	0
349	Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin. Journal of Hypertension, 2009, 27, 2116-2117.	0.3	0
350	In the Identification of Cardiovascular Risk With the SCORE Model, Could We Recommend Its Calculation Interchangeably With Total Cholesterol or Atherogenic Index? Concordance Between Total Cholesterol and Atherogenic Index in the SCORE Table. Revista Espanola De Cardiologia (English) Tj ETQq0 0 0 rBT /Overlock 10 T	0.4	0
351	Response to Estimation of Aortic Blood Pressures and Pulse Wave Velocity in Obese Children: A Technological Perspective. Hypertension, 2012, 60, .	1.3	0
352	Necessity of add-on therapy in the treatment of hypertension. Journal of Hypertension, 2012, 30, 2085-2087.	0.3	0
353	Reply. Journal of Hypertension, 2015, 33, 2551.	0.3	0
354	JS ISH-ESH-1 EVALUATION OF RENAL FUNCTION AT BASELINE AND DURING TREATMENT. Journal of Hypertension, 2016, 34, e192.	0.3	0
355	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.3	0
356	Reply. Journal of Hypertension, 2017, 35, 2551-2552.	0.3	0
357	Niveles de complejidad asistencial en pacientes con cÃ³digos diagnÃ³sticos de insuficiencia cardiaca en una poblaciÃ³n. Revista Espanola De Cardiologia, 2018, 71, 687-688.	0.6	0
358	Immigration and hypertension in youths learning from one country's experience. Journal of Hypertension, 2019, 37, 680-682.	0.3	0
359	Environmental metals and metal mixtures and renal disease in an adult population from Spain: the Aragon Workers Health Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
360	Genetic variation and urine cadmium levels: ABCC1 effects in the Strong Heart Family Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0

#	ARTICLE	IF	CITATIONS
361	Diabetic Kidney Disease. , 2010, , 319-339.		0
362	Ambulatory Blood Pressure in Clinical Practice: Clinical Relevance of Circadian Rhythm and Nocturnal Dip. , 2012, , 59-69.		0
363	The Role of ABPM in Evaluation of Hypertensive Target-Organ Damage. , 2013, , 505-515.		0
364	Proteinuria-Microalbuminuria in Renal Damage. , 2015, , 159-164.		0
365	Glomerular Filtration Rate in Renal Damage. , 2015, , 165-170.		0
366	The Role of ABPM in Evaluation of Hypertensive Target-Organ Damage. , 2017, , 1-14.		0
367	The Role of ABPM in Evaluation of Hypertensive Target-Organ Damage. , 2018, , 727-740.		0
368	Evidences from Clinical Trials and Use of Antihypertensive Drugs in Children and Adolescents. Updates in Hypertension and Cardiovascular Protection, 2019, , 263-277.	0.1	0